Navigation Links
K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
Date:7/15/2010

ain assets, and the terms of such transactions;
  • the possibility that default on one type or class of the Company's indebtedness could result in cross default under, and the acceleration of, its other indebtedness;
  • the risks that present or future changes in the Board of Directors or management may lead to an acceleration of the Company's bonds or to adverse actions by government agencies or our auditors;
  • if a director of our company, or a shareholder with an ownership interest in our company of 5% or more, is excluded from participating in federal or state health care programs, then HHS may use its discretionary authority to also exclude our company from participation in federal healthcare programs;
  • the risk that the failure to comply with the quantitative listing standards of the New York Stock Exchange, including with respect to minimum share price and public float, could result in delisting of our shares on the New York Stock Exchange, which would harm the market price of the Company's Class A common stock and Class B common stock;
  • the risk that the Company will be unable to engage a successor independent registered public accounting firm promptly or be unable to complete the review of its Annual Report on Form 10-K for its fiscal year ended March 31, 2010 promptly, which would impact the Company's compliance with New York Stock Exchange listing standards, and the Securities Exchange Act of 1934, as amended;
  • delays in retaining successor auditors; and
  • the risks detailed from time-to-time in the Company's filings with the SEC.

  • This discussion is not exhaustive, but is designed to highlight important factors that may impact the Company's forward-looking statements.

    Because the factors referred to above, as well as the statements included elsewhere in this press release, could cause actual results or outcom
    '/>"/>

    SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
    2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
    9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... DALLAS , July 24, 2014 /PRNewswire-iReach/ -- ... days once order is placed. Photo ... is a professional and in-depth market survey on ... firstly reviews the basic information of Hemodialysis Machine ... report then explores global and China,s top manufacturers ...
    (Date:7/24/2014)... Cancer patients in the west of ... closer to home when a new radiotherapy center opens near ... (NYSE: VAR ) has been selected to equip ... for four TrueBeam™ medical linear accelerators. Two ... radiotherapy and radiosurgery treatments, will replace older treatment machines at ...
    (Date:7/24/2014)...  Blueprint Medicines (Blueprint), a leader in discovering highly ... announced the appointment of Jeffrey Albers as ... Algeta ASA, where he served on the executive management ... Bayer. Mr. Albers succeeds Alexis Borisy , co-founder ... Rock Ventures, who will remain an active member of ...
    Breaking Medicine Technology:Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer 2
    ... ATLANTA, May 30, 2012 Advanced automation, sophisticated eScribe ... portal are among the new innovations showcased in Elekta,s ... of Clinical Oncology (ASCO) Annual Meeting, June 1-4, at ... for the sixth consecutive year, Elekta (booth #4019) ...
    ... 30, 2012  Actavis Group, an international generic pharmaceuticals ... approval of Nifedipine Extended-Release Tablets, USP, 90mg, a ... the product has commenced.  Nifedipine ... $23 million for the 12 months ending December ...
    Cached Medicine Technology:Elekta to Demonstrate Latest MOSAIQ OIS Innovations for Oncology Practices at 2012 ASCO Annual Meeting 2Elekta to Demonstrate Latest MOSAIQ OIS Innovations for Oncology Practices at 2012 ASCO Annual Meeting 3Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP) 2
    (Date:7/24/2014)... 2014 National Analysts Worldwide, the Philadelphia-headquartered ... will operate globally under the name, NAXION , ... Employee Stock Ownership Plan (ESOP) organization led by majority ... . The firm guides market strategy in target ... , Said McDonald, “We wanted our name to better ...
    (Date:7/24/2014)... The report, “Feed Palatability Enhancers & ... (Swine, Poultry, Cattle, Pets, Aquaculture, and Others) - Global ... feed palatability enhancers & modifiers market with an analysis ... value, of types of feed flavors, sweeteners, and text ... figures spread through 275 pages and in-depth TOC on ...
    (Date:7/24/2014)... and faster, according to a new study published in ... to tackle melanoma, the most deadly form of skin ... of Manchester found that some melanoma cells are particularly ... surrounding tissue, while other melanoma cells are the opposite ... tumour, the faster growing cells ,piggy-back, along with the ...
    (Date:7/24/2014)... The Biofeedback Federation of ... distribution agreement with game development company Zukor Interactive. ... groups to offer Zukor's Grind , a ... neurofeedback in European and international markets. , Zukor's ... to be used as a biofeedback/neurofeedback training tool. ...
    (Date:7/24/2014)... WEDNESDAY, July 23, 2014 (HealthDay News) -- Even though its ... best known as Tylenol -- does not help treat lower ... The researchers found the drug was no more effective than ... acute lower back pain. Besides showing no effect in ... help in improving sleep woes tied to back pain, nor ...
    Breaking Medicine News(10 mins):Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4Health News:Piggy-backing cells hold clue to skin cancer growth 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 3Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 2Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 3
    ... ... year’s edition of The Leading Physicians of the World. With a long track record of ... of the World wanted to honor the specialty so integral to the surgical team; anesthesiology. ... (PRWEB) June 26, 2010 ...
    ... ... by whiplash injury should be made aware of their legal entitlement to file a whiplash ... ... leading whiplash injury claims lawyers, is today warning of the need for greater awareness of ...
    ... ... Haitian children, mostly refugees and orphans who go all day without eating. Shelene Bryan and ... ... and her Skip1 team of volunteers were deep inside Haiti and the Dominican Republic delivering ...
    ... ... a renewable resource. , ... June 26, 2010 -- Laser and copier toners use over 146,000,000 gallons of oil per ... or Forestry products, therefore, eliminating the need for petroleum products. The term bio-product is ...
    ... studying and treating disease and for the practice of ... the cells that may one day be transplanted into ... studies going on worldwide, scientists at the UCLA Broad ... X chromosome inactivation take place in very early passages ...
    ... By Maryann Mott HealthDay Reporter , FRIDAY, June ... chuckle out of watching their dog sleep while its paws race ... in dreamland, and scientists say they were right: Pets do ... of past events replay in their minds much the same way ...
    Cached Medicine News:Health News:The International Association of Anesthesiologists Places its Top Doctors in the Renowned Medical Publication, The Leading Physicians of the World. 2Health News:The International Association of Anesthesiologists Places its Top Doctors in the Renowned Medical Publication, The Leading Physicians of the World. 3Health News:Whiplash Claims Warns on Awareness of Personal Injury Compensation Entitlement 2Health News:Shelene Bryan and Skip1.org Help Build Kitchen for Haitian Orphans 2Health News:Great Office Buys Announces the Addition of Elite Brand Bio-Based Toners to their Product Line 2Health News:Chromosomal variations found in early passage female embryonic stem cells 2Health News:Chromosomal variations found in early passage female embryonic stem cells 3Health News:Where Do Pets Go When They Dream? 2Health News:Where Do Pets Go When They Dream? 3
    ... heavy duty, controlled stretch knee support that ... allowing full range of motion. The ... the knee, and help to keep the ... This is an excellent support for ...
    ... breathable foam. Three piece design for precise ... loop closures. Lightweight rigid posterior stays with ... with optional hot and cold therapy Gel ... pain cycle by providing cold therapy to ...
    ... Scoring: , One of the outstanding features ... our patented Three-Dimensional Molding Technology. , This ... brace which effectively controls the bunching and ... comfort to the wearer. , ...
    ... new padding system from Innovation Sports. Exceptionally ... contours to the unique anatomy of each ... Gel Fit's proprietary Octogrip™ Anti-Slip System improves ... when the brace is strapped on. Gel ...
    Medicine Products: